This is our second update on the litigation (you can see the prior analyses here and here, in addition to a parallel post on our companion...
Daniel McCallum
- Posts: 6
-
-
Several of the Federal Circuit’s initial decisions involving the Biologics Price Competition and Innovation Act (the “BPCIA”) focused...
-
This article provides an update on our prior analysis of the infliximab litigation involving Janssen Biotech, Inc. (“Janssen”),...
-
Genentech filed suit against Amgen this past February when a dispute arose between the parties during the first step of the “patent...
-
Editors’ Note: Although the BPCIA was enacted seven years ago, to date, only four biosimilar products have been approved by the FDA, and...
-
Genentech’s lawsuit against Amgen has come to a quick (although perhaps temporary) end, with the Court dismissing Genentech’s complaint...